• Braeburn Pharmaceuticals, which markets and develops treatments for opioid addiction, has filed for a $150 million IPO. The offering notes that Apple Tree Partners has agreed to buy $40 million in stock. Here’s the S-1.
• The UK’s Tiziana Life Sciences has bagged a global license for the IL-6R antibody NI-1201 from Novimmune. The companies did not spell out the financial terms of the deal. “We view NI-1201 as a potential game-changer for addressing the high unmet need of autoimmune and inflammatory diseases” commented Gabriele Cerrone, Chairman of Tiziana Life Sciences. “The acquisition of NI-1201 not only strengthens our business strategy of developing novel fully human mAbs to treat life-threatening inflammatory diseases such as non-alcoholic steatohepatitis (NASH) and rheumatoid arthritis, but expands our potential to leverage the pioneering work we are doing with foralumab, the oral anti-CD3 mAb to treat autoimmune and inflammatory diseases.”
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 25,000+ biopharma pros who read Endpoints News by email every day.Free Subscription